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Abstract: A nutritional approach could be a promising strategy to prevent or slow the progression of
neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease, since there is no effective
therapy for these diseases so far. The beneficial effects of omega-3 fatty acids are now well established
by a plethora of studies through their involvement in multiple biochemical functions, including
synthesis of anti-inflammatory mediators, cell membrane fluidity, intracellular signaling, and gene
expression. This systematic review will consider epidemiological studies and clinical trials that
assessed the impact of supplementation or dietary intake of omega-3 polyunsaturated fatty acids on
neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Indeed, treatment with
omega-3 fatty acids, being safe and well tolerated, represents a valuable and biologically plausible
tool in the management of neurodegenerative diseases in their early stages.
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1. Introduction
Several cerebral functions are determined by some nutrients, such as omega-3 polyunsaturated
fatty acids (PUFAs), which are parts of the plasma membrane implicated in several processes, including
increased synaptic development and functionality [1], effects on synaptic integrity and plasticity [2–5],
contributing to neuroplasticity and subsequent enhancement of cognitive activity [6].
There is accumulating scientific evidence on the possible efficacy of PUFAs supplementation in
neurodegenerative disorders [7,8], such as Parkinson’s (PD) and Alzheimer’s disease (AD) [9–13].
Although dietary recommendations are far from being a treatment for PD or AD, they may be able to
alleviate some of the symptoms or slow the cognitive and physical decline.
The present study systematically reviews the effects of omega-3 polyunsaturated fatty acids’
supplementation on cognitive function in patients with Parkinson’s or Alzheimer’s disease.
The main classes of PUFAs belong to the omega-3 one, which comprises α-linolenic acid (ALA,
18:3 ω-3), eicosapentaenoic acid (EPA, 20:5 ω-3) and docosahexaenoic acid (DHA, 22:6 ω-3) and to the
omega-6 one, which comprises linoleic acid (LA, 18:2ω-6) and arachidonic acid (ARA, 20:4ω-6) [14]
(Table 1). DHA and ARA are the most important PUFAs in the brain [15]. In particular, DHA constitutes
over 90% of theω-3 PUFAs and 10–20% of total lipids in the brain [16]. It is mainly incorporated in
phosphatidylethanolamine, phosphatidylserine and in smaller amounts in phosphatidylcholine [17]
at synaptic terminals, mitochondria and endoplasmic reticula. Indeed, DHA is able to modulate
cellular properties and physiological processes such as membrane fluidity, release of neurotransmitters,
gene expression, myelination, neuroinflammation and neuronal growth [18,19].
DHA results from ALA, while ARA from LA by desaturation and elongation of the carbon
chain [20] (Figure 1). Humans can synthesize saturated and monounsaturated fatty acids (MUFAs),
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but they are not able to synthesize ALA and LA due to the deficiency of the conversion enzyme
ω-3-desaturase [21]. LA and ALA request the same conversion enzymes, consequently there is
competitive inhibition between the two substrates. Delta-6-desaturase promotes the conversion of
omega-3 fatty acids into omega-6 fatty acids. However, an increased LA intake may shift the balance
towards the conversion of omega-6 PUFA thus inhibiting the conversion of ALA to DHA [22].
Table 1. Fatty acids’ categories.
Fatty Acids
Saturated Unsaturated
MUFA PUFA
omega-9 omega-3 omega-6
stearic acid 18:0 oleic acid 18:1
ALA 18:3
EPA 20:5
DHA 22:6
LA 18:2
ARA 20:4
Esterified DHA in food, is released by the intestinal lipases in free unesterified form (DHA-FFA) in
the small intestine and, after intestinal and hepatic metabolism, it can be found esterified in triglycerides
and in phosphotidylcholine or as free DHA linked to low-density lipoprotein or albumin [15].
Endothelial lipases, fatty acid-binding proteins (FABP) and apolipoprotein E (ApoE) [23–26] dissociate
the different forms in the blood-brain barrier (BBB) with both active and passive mechanisms [27].
The DHA, via FABP [24,25] and ApoE produced by astrocytes, [26] is transported within the central
nervous system.
DHA is incorporated into membrane phospholipids mainly in the stereospecifically numbered-2
position through the action of coenzyme A [28]. However, through hydrolysis reactions catalyzed by
phospholipase, DHA can be released from membrane phospholipids. Both synthesis and hydrolysis
represent mechanisms aimed at responding to dynamic cellular events and challenges during
development and aging [14].
DHA, EPA, and ARA are also important for the production of eicosanoids (prostaglandins,
thromboxanes, leukotrienes) and, therefore, for their involvement in inflammation [20].
The phospholipase A2 enzymes (PLA2) hydrolyze the phospholipid by releasing fatty acids. As a result
of an inflammatory stimulus involving specific cell activation, therefore, there is an increase in the
levels of free fatty acids. Three types of PLA2 are mainly implicated in the release of bioactive lipids:
the cytosolic calcium-dependent PLA2 (cPLA2), the cytosolic calcium-independent PLA2 (iPLA2) and
the secretory PLA2 (sPLA2) [29]. Among them, cPLA2, shows a substrate specificity for phospholipids
containing arachidonic acid (AA). cPLA2, however, can also hydrolyze phospholipids containing
EPA, but the low abundance of this fatty acid allows cPLA2 to release AA in specific conditions [30].
Inflammatory modulation is regulated by prostaglandins, leukotrienes, and thromboxanes, which are
metabolized by cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) [31]. ARA is antecedent to the
2-series prostaglandins, as well as to thromboxanes and to 5-series leukotrienes [22]. Consequently,
ARA has pro-inflammatory effects, while EPA has anti-inflammatory actions [22]. Furthermore, 5-LOX
is responsible for the generation of anti-inflammatory eicosanoids such as the D-series resolvins,
protectins and maresins, which are derived from DHA and the E-series resolvins from EPA [32,33]
(Figure 1).
Human metabolic studies show a limited conversion of ALA to DHA, typically below 5% in adult
males [34–37]. Women have a greater efficiency of conversion than men [38] and this may be important
for fetal supply during pregnancy. Women demonstrated lower omega-3 fatty acid intake than men
considering the same age categories [39]. Moreover, delta-6 desaturase activity decreases with age
and undergoes lesser conversion, mainly in women. Therefore, to get the sufficient intake of EPA and
DHA, especially in aging dietary supplements containing these preformed omega-3 are necessary.
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Indeed, the shift in modern diets towards reduced omega-3 PUFA intake increases omega-6 PUFA
consumption and, if combined with less physical activity, has a detrimental impact on development
and aging, especially with regard to cognitive function [14].
Current guidelines suggest an intake of EPA and DHA within the range of 250 to 500 mg [40].
As indicated by modern daily dietary, the consumption of omega-3 PUFAs is lower than necessary.
DHA intakes, indeed, are closer to 100 mg per day, the optimal dietary omega-6 to omega-3 PUFA
ratio has been determined in 2:1 or lesser, whereas the Western diet is usually established in the range
of 10:1 to 25:1 [14].
The DHA daily dose necessary to induce significant positive results still requires further research.
For example, a portion of 135 g of Atlantic salmon is necessary to reach 2 g/die of DHA [41] (Table 2).
Thus, it is very difficult to achieve such high DHA consumption without integrations [7].
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Baked beans, canned, vegetarian 0.07   
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Bread, whole wheat 0.04   
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Figure 1. Endogenous synthesis of omega-3 polyunsaturated fatty acids and their involvement in
inflammation. 15-LOX: 15-Lipoxygenase, 5-LOX: 5-Lipoxygen se, 12/15-LOX: 12/15 Lipoxyg ase,
CYP-450: Cytochrome P4 0.
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Table 2. Amount of α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA).
Food ALA g/Portion EPA g/Portion DHA g/Portion
Baked beans, canned, vegetarian 0.07
Black walnuts 0.76
Bread, whole wheat 0.04
Canola oil 1.28
Chia seeds 5.06
Chicken, breast, roasted, 0.01 0.02
Cod, Pacific, cooked * 0.04 0.10
Edamame, frozen, prepared 0.28
Egg, cooked 0.03
English walnuts 2.57
Flaxseed oil 7.26
Flaxseed, whole 2.35
Ground beef, 85% lean, cooked ** 0.04
Herring, Atlantic, cooked * 0.77 0.94
Kidney beans, canned 0.10
Lobster, cooked * 0.04 0.10 0.07
Mackerel, Atlantic, cooked * 0.43 0.59
Mayonnaise 0.74
Milk, low-fat (1%) 0.01
Oysters, eastern, wild, cooked 0.14 0.30 0.23
Refried beans, canned, vegetarian 0.21
Salmon, Atlantic, farmed, cooked 0.59 1.24
Salmon, Atlantic, wild, cooked 0.35 1.22
Salmon, pink, canned, drained * 0.04 0.28 0.63
Sardines, canned in tomato sauce,
drained * 0.45 0.74
Scallops, cooked * 0.06 0.09
Sea bass, cooked * 0.18 0.47
Shrimp, cooked * 0.12 0.12
Soybean oil 0.92
Tilapia, cooked * 0.04 0.11
Trout, rainbow, wild, cooked 0.40 0.44
Tuna, light, canned in water, drained * 0.02 0.17
Tuna, yellowfin, cooked * 0.01 0.09
* Except as noted, the USDA database does not specify whether fish are farmed or wild-caught. ** The United States
Department of Agriculture Food Composition Databases does not specify whether beef is grass-fed or grain-fed.
Data from Office of Dietary Supplements, National Institute of Health (NIH) [42,43].
2. Parkinson’s Disease
Parkinson’s disease is a progressive neurodegenerative disorder characterized by loss of
dopaminergic neurons in the substantia nigra, pars compacta. A pathological hallmark of the
disease is also the presence of Lewy bodies, which are intracellular inclusions enriched in the protein
α-synuclein.
The common symptoms include tremor, rigidity, bradykinesia and postural insecurity,
with dementia and depression observed in the advanced stages of the disease [29]. In many instances,
depression occurs before motor symptoms, which are typical expressions of Parkinson’s classic onset.
In a recent study, it has also been shown that people suffering from depression are three-fold more
predisposed to develop PD [44]. Depression, which affects a third of PD patients, combined with
anxiety, apathy, and anhedonia further renders the PD outcomes even more complicated [29].
Although the etiology is currently unknown, there are a number of putative risk factors
(e.g., exposure to environmental toxins) [45] and the pathogenic mechanisms include mitochondrial
dysfunction, neuroinflammation, and oxidative stress [46]. However, numerous studies support that a
diet rich in PUFAs or supplementation with food products containing EPA and DHA could alleviate
some of the patients’ symptoms. The main scales used to evaluate PD symptoms are summarized in
Table 3.
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Table 3. Summary of main scales used for assessment of Parkinson’s and Alzheimer’s Disease ([47]
with modifications).
Main Scales Description
Activities of Daily Living
ADCS-ADL, ADCS-IADL
It measures the functional ability to perform activities of daily life. ADL
assess basic living skills such as bathing and eating, whereas Instrumental
activities of daily living (IADL) measures more complex tasks such as
using the telephone or preparing meals. A higher ADL or IADL score
indicates a worsening functionality.
Alzheimer’s Disease
Assessment Scale-Cognitive
Subscale (ADAS-Cog)
It is a sensitive and reliable method for the assessment of cognitive
function in dementia. It consists of a psychometric scale of 11 items, and
scores range from 0 (no impairment) to 70 (very severe impairment).
Beck Depression Inventory
(BDI)
It is a 21-question multiple-choice self-report inventory, one of the most
widely used psychometric tests for measuring the severity of depression.
Brief Assessment Schedule
Depression Cards (BASDEC)
It is a brief test for screening depression, requiring minimal training to
administer.
Bristol’s Activities of Daily
Living Scale (BADLS)
It is specifically designed for individuals with mild dementia living in the
community for completion by caregivers.
Clinical Dementia Rating
(CDR)
It is a global measure that assesses memory, orientation, judgment, and
other features. Is based on caregiver interview. Classifies dementia into
questionable, mild, moderate, and severe.
Clinical Global Impression
Scale (CGI)
It measures symptom severity, treatment response, and the efficacy of
treatments in treatment studies of patients with mental disorders.
Clinician Interview-Based
Impression of Change, plus
carer interview (CIBIC-Plus)
It is a global measure capable of detecting changes in cognition,
functionality, and behavior, thus assessing dementia’s severity and
progression. Requires separate interviews with patients and caregivers.
Diagnostic and Statistical
Manual of Mental Disorders,
fourth edition (DSM-IV)
It is the handbook used by health care professionals in the United States
and much of the world as the authoritative guide to the diagnosis of
mental disorders.
Hamilton Depression Rating
Scale (HDRS)
Is the most widely used clinician-administered depression assessment
scale. The original version contains 17 items pertaining to symptoms of
depression experienced over the past week.
Hoehn and Yahr scale It is a commonly used system for describing how the symptoms of PDprogress.
Hopkins Verbal Learning
Test–Revised (HVLT-R)
It is a brief verbal learning and memory test ideal in situations calling for
repeated neuropsychological examinations.
Mini-Mental State Examination
(MMSE)
It evaluates cognitive function in the areas of orientation, memory,
attention, calculation, language, and visual construction. It is widely
translated and used in clinical practice. Patients score between 0 and 30
points, and cutoffs of 23/24 have typically been used to show significant
cognitive impairment.
Montgomery–Åsberg
Depression Rating Scale
(MADRS)
It is a ten-item diagnostic questionnaire which psychiatrists use to measure
the severity of depressive episodes in patients with mood disorders.
Neuropsychiatric Inventory
(NPI)
It assesses dementia-related behavioral symptoms. The NPI originally
examined 10 sub-domains of behavioral functioning: Delusions,
hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy,
disinhibition, irritability/lability, and aberrant motor activity.
Neuropsychological test
battery (NTB)
This scale assesses changes in cognitive function and is seen as a
promising method for mild AD. NTB has shown to be able to detect
changes in memory performance.
Unified Parkinson’s Disease
Rating Scale (UPDRS) It evaluates motor impairment and disability of patients with PD.
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2.1. The Role of Omega-3 Polyunsaturated Fatty Acids in PD: Observational Studies
The first major prospective study concerning environmental, lifestyle, and physical precursors of
clinical Parkinson’s disease is the Honolulu-Asia Aging Study [48], which started in 1965 and included
a cohort of 8006 Japanese-American men, during a 30-year follow-up. Among the dietary factors
showing an inverse association with PD, the polyunsaturated fats [48] were included (Table 4).
Table 4. Prospective observational studies assessing the impact of omega-3 fatty acids supplementation
in Parkinson’s disease PD patients.
N◦ Patients PopulationCharacteristic
Type and Dose
Supplementation
Exposure
Period Results References
8006
PD
Honolulu-Asia
Aging Study
Food frequency
questionnaire 30 years
Omega-3 PUFAs
appeared
protective.
[48]
5289
PD Rotterdam
Study The
Netherlands
Semiquantitative
food frequency
questionnaire
6 years
Intakes of omega-3
PUFAs were
significantly
associated with a
lower risk of PD.
[49]
131,368
PD Health
Professionals
Follow-Up
Study and the
Nurses’ Health
Study USA
Semiquantitative
food frequency
questionnaire
16 years
High intakes of
fruit, vegetables,
whole grains,
legumes, poultry,
and fish were
associated with a
lower risk of PD.
[50]
249 PD Japan
Self-administered
diet history
questionnaire
6 years
Consumption of
omega-3 PUFA,
ALA, EPA, DHA
was not associated
with PD.
[51]
In The Rotterdam Study, the intakes of total fats, MUFAs and PUFAs were significantly associated
with a lower risk of PD, by means of energy-adjusted intake of fat and fatty acids [49].
The association between dietary lifestyle and the risk of PD was evaluated in two most important
studies: The Health Professionals Follow-Up Study (1986–2002) and the Nurses’ Health Study
(1984–2000), including 131,368 men and women. Two dietary styles have been identified and compared:
Prudent diet, characterized by high consumption of fruit, vegetables and fish and Western diet. It was
demonstrated that the prudent diet significantly reduced PD risk, while the Western diet did not [50].
However, a case-control study, which examined the relationship between dietary intake of
individual fatty acids and the risk of PD in Japan, including 249 cases within six years of onset of PD,
demonstrated that, if the higher consumption of ARA and cholesterol could be related to an increased
risk of PD, the intake of omega-3 polyunsaturated fatty acids was not [51].
In summary, we can conclude that prospective observational studies showed an association
between a diet rich in polyunsaturated omega-3 fatty acids with a lower risk of PD.
2.2. The Role of Omega-3 Polyunsaturated Fatty Acids in PD: Randomized, Double-Blind, Placebo-Controlled
Clinical Trials
Randomized, double-blind, placebo-controlled clinical trials involving PD are few for several
reasons: poor patient adherence to diet therapy, duration of dietary treatment, control of clinical
parameters and evaluation of these same parameters. When the pathology occurs, already 70% of
neurons are compromised. Thus, thinking that only a dietary treatment can restore brain functions
is really a utopia. However, dietary treatments with omega-3 fatty acids may have advantages in
reducing inflammation and, consequently, depressive symptoms.
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Indeed, treatment for six months with 800 mg/day DHA and 290 mg/day EPA from fish oil,
demonstrated, in the DHA-treated patients, a reduction of 50% in the Hamilton rating scale for
depression (HDRS) total score if compared with the placebo group which took corn oil. DHA
integration reduced depressive symptoms [52]. However, treatment had no statistically significant
effect on the rate of change on either unified Parkinson’s disease rating scale (UPDRS) or Hoehn-Yahr
scale score [52] (Table 5).
Table 5. Clinical trials assessing the impact of omega-3 fatty acids supplementation in PD patients.
N◦ Patients PopulationCharacteristics
Type and Dose
Supplementation
Exposure
Period Results References
24 PD Italy
800 mg/die DHA
+ 290 mg/die EPA
from fish oil
Placebo: Corn oil
6 months
Treatment had no
statistically
significant effect on
the rate of change
on either UPDRS or
Hoehn-Yahr Scale
score. In
DHA-treated
patients, the HDRS
score was reduced
by at least 50%.
[52]
31
PD and Major
Depression
(DSM-IV) Brazil
480 mg/die DHA
+ 720 mg/die EPA
from fish oil +
tocopherol
Placebo: Mineral
oil
3 months
Treatment had no
statistically
significant effect on
the rate of change
on Hoehn-Yahr
Scale score, but
there was a
significant decrease
in MADRS and
CGI scores.
[44]
60 PD Iran
1000 mg omega-3
fatty acids from
flaxseed oil + 400
IU vitamin E
Placebo: Not
specified
3 months
Treatment had
favorable effects on
UPDRS score.
[53]
Another double-blind, placebo-controlled study analyzed the effect of fish oil supplementation in
parkinsonian patients with depression measured using Montgomery–Asberg rating scale (MADRS),
the clinical global impressions scale (CGI) and Beck depression inventory (BDI) [44]. After three months,
the supplementation with four capsules of omega-3 from fish oil (each capsule containing 180 mg EPA,
120 mg DHA and tocopherol) showed a significant decrease in MADRS and CGI-depression scores
while there was no difference among treated and control groups in BDI [44]. Moreover, Parkinson’s
symptoms, measured by Hoehn and Yahr scale, did not show significant variation during the three
months of supplementation in all groups observed [44].
A randomized double-blind placebo-controlled clinical trial, conducted in 60 patients with PD,
receiving either 1000 mg omega-3 fatty acids from flaxseed oil plus 400 IU vitamin E supplements
or placebo for three months, showed that the dietetic supplementation in people with PD improved
UPDRS, compared with the placebo [53].
The published papers give an important indication on the use of omega-3 supplements, especially
for depression in PD. However, the number of patients recruited is small and also the types of
supplements vary. It is widely demonstrated that the effective dose is 1 g/day of DHA. Animal or algal
sources ensure a correct intake of DHA, while plant sources are often ineffective, since only 10% of ALA
is metabolized to DHA. Despite this, the supplementation of omega-3 from linseed oil and vitamins
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E had favorable effects not only on UPDRS but also on high-sensitivity C-reactive protein (hs-CRP),
total antioxidant capacity (TAC), glutathione and markers of insulin metabolism [53]. Furthermore,
the three-to-six-month treatment is a relatively short period considering that we deal with dietary
intervention in a pathology where the main symptoms are already evident [44,52,53].
3. Alzheimer’s Disease
Alzheimer’s Disease is a neurodegenerative syndrome that includes most cases of dementia,
affecting over 35 million people all over the world. AD typical clinical features consist of cognitive
impairment, memory loss, language disorders, rapid changes in mood and behavior, time- and
space-disorientation, inhibition of the patients’ daily habits. The neurodegenerative process observed
in AD is usually present in patients’ brain before the appearance of the first symptoms [54].
Neurofibrillary tangles, senile plaques, neuronal loss, and consequential brain atrophy represent
the main features of AD.
Neurofibrillary tangles are formed by hyperphosphorylation and truncation of a protein, known
as tau, which normally forms and stabilizes cytoskeleton by interaction with tubulin. As a result
of the above-mentioned post-transcriptional modifications, tau protein can form toxic aggregates
(i.e., neurofibrillary tangles) mainly situated in the hippocampus. Moreover, tau protein dysfunction
produces cytoskeleton deconstruction as a result of microtubule disintegration, producing synaptic
failure that produces a loss of communication and contributes to AD neurodegeneration.
Tau hyperphosphorylation also hinders mitochondrial transport since it is affected by
interactions with microtubules, causing energy deficits in presynaptic areas that may result in a
synaptic discontinuance.
The amyloid precursor protein (APP) degradation originates senile plaques constituted by
extracellular deposits of β-amyloid peptide (Aβ) which induce inflammation and neuronal death. APP,
a transmembrane protein present in neurons, can undergo cleavage by two different pathways: the
amyloidogenic and the non-amyloidogenic ones, both mediated by secretases: β- and γ-secretases
are involved in the first one, while α- and γ-secretases in the second one (Figure 2) [54]. In the
non-amyloidogenic pathway, APP is sequentially cleaved by α-secretase and γ -secretase, generating
truncation products: Aβ17–40/42 peptides (Figure 2). In the amyloidogenic pathway, APP is sequentially
cleaved by β-secretase and γ-secretase, leading to whole-length Aβ peptides, responsible for the
development of the plaques. While non-amyloidogenic pathway produces the amino-terminal
fragment APPsα and the carboxy-terminal one C83, the amyloidogenic one produces APPsβ and
C99. The activity of γ-secretase produces the APP intracellular domain (AICD), which takes part in
the cellular signaling. Based on the point where γ-secretase generates the cut in the amyloidogenic
pathway, the whole-length Aβ peptide would undergo different reductions: Aβ1–40 and Aβ1–42 are
the main brain fragments (Figure 2) [54]. In the amyloidogenic processing, DHA decreased the β-
and γ-secretase activity, while in the non-amyloidogenic processing it increased ADAM17 protein
level, caused by a decreased protein degradation and an increased expression level [55]. Moreover,
DHA lowers amyloidogenic processing by modifying both β- and γ-secretase activity with different
mechanisms [55].
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Figure 2. Amyloid precursor protein (APP) processing pathways. The non-amyloidogenic pathway
(a) occurs upon sequential cleavage byα- andγ-secretases (non-pathological situation). The amyloidogenic
pathway route (b) occurs when cleavage is carried out sequentially by β- and γ secretases (pathological
situation). Letters α, β, and γ represent each type of secretase. APP: Amyloid precursor protein, APPsα:
Soluble α-APP, APPsβ: Soluble β-APP. Omega-3 polyunsaturated fatty acids, proposed to inhibit APP
processing, are shown in orange dashed lines.
3.1. The Role of Omega-3 Polyunsaturated Fatty Acids in AD: Observational Studies
Prospective epidemiological studies performed in the Netherlands, USA, and France strongly
supported a causal associati n between low fish an /or low DHA intake and AD. Most of the seven
pros ective studies published sho that an increased intake of fish or omega-3 PUFA decreases the
risk of AD (Table 6) [56].
Table 6. Prospective observational studies assessing the impact of omega-3 fatty acids supplementation
in AD patients.
N◦ Patients PopulationCharacteristic
Type and Dose
Supplementation
Exposure
Period Results References
5386
AD 37 Rotterdam
Study The
Netherlands
Semiquantitative
food frequency
questionnaire
2.1 years
Fish consumption,
an important source
of omega-3 PUFA,
was inversely related
to incident dementia,
in particular to
Alzh imer’s disease.
[57]
815
AD 131 Chicago
Health and
Aging Project
USA
Food frequency
questionnaire 3.9 years
Dietary intake of
omega-3 PUFA and
weakly consumption
of fish may reduce
the risk of
Alzheimer’s disease.
[58]
2233
AD 190
Cardiovascular
Health Cognition
Study (CHCS)
USA
Food frequency
questionnaire 5.4 years
Consumption of fatty
fish more than twice
per week was
associated with a
reduction in the risk
of Alzheimer’s
disease by 41%.
[59]
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Table 6. Cont.
N◦ Patients PopulationCharacteristic
Type and Dose
Supplementation
Exposure
Period Results References
488
AD not reported
The Framingham
Heart Study USA
Semiquantitative
food frequency
questionnaire
9.1 years
Plasma DHA level
was associated with
a significant 47%
reduction in the risk
of developing
all-cause dementia.
[60]
8085
AD 183
Three-City cohort
study France
Food frequency
questionnaire 3.48 years
Frequent
consumption of
fruits and vegetables,
fish, and omega-3
rich oils may
decrease the risk of
dementia and
Alzheimer’s disease,
especially among
ApoE ε4 noncarriers.
[61]
5395 Rotterdam StudyThe Netherlands
Semiquantitative
food frequency
questionnaire
9.6 years
In the cohort with
moderate
consumption of fish
and omega-3 PUFAs
these dietary factors
did not appear to be
associated with
long-term dementia
risk
[62]
923
AD Rush
Memory and
Aging Project
USA
Semiquantitative
food frequency
questionnaire
4.5 years
High adherence to all
three diets may
reduce AD risk.
[63]
The Rotterdam Study was the first to report that fish intake was inversely related to incidence of
dementia, in particular to Alzheimer’s disease [57]. The data are confirmed by subsequent studies
where the consumption of omega-3 [58] or fatty fish [59] or adherence to a diet rich in fruit, vegetables,
fish, and oils rich in omega-3 [60–63], is associated with a reduction in AD risk. Subjects that had a mean
DHA intake of 0.18 g/die (mean fish intake of three servings per week) have a lower relative risk of
developing dementia if compared with subjects assuming lower DHA intake (0.15 g/die corresponding
to mean fish intake of two servings per week).
Only a study published by Devore et al. [62] showed that differential consumption of fish
(either 8.2 g/die or 29.6 g/die, defined as low or high medians) and omega-3 PUFAs, does not appear
to be associated with long-term dementia risk. Results were also null for dietary intakes of EPA
(0.03–0.08 d/die) and DHA (0.002–0.16 g/die) considering AD as the outcome of interest.
3.2. The Role of Omega-3 Polyunsaturated Fatty Acids in AD: Randomized, Double-Blind, Placebo-Controlled
Clinical Trials
The first randomized clinical trial controlled by placebo (OmegAD Study) that evaluated omega-3
fatty acids’ impact in AD was published in 2006 [64] (Tables 3 and 7).
A study by Freund-Levi et al. [64] evaluated omega-3 fatty acids’ supplementation in 204 subjects
with mild to moderate AD. The active group received daily omega-3 fatty acids (1720 mg DHA and
600 mg EPA) while the placebo group received 4000 mg of corn oil (containing 2400 mg LA) for six
months. Both groups received an additional six-month supplementation with omega-3 fatty acids.
Medication for AD treatment was allowed. No significant difference was shown after a 6- or 12-month
treatment between groups in Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog),
mini-mental state examination (MMSE) and clinical dementia rating (CDR).
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Table 7. Clinical trials assessing the impact of omega-3 fatty acids supplementation in AD patients.
N◦ Patients PopulationCharacteristic
Type and Dose
Supplementation
Exposure
Period Results References
204
AD (DSM-IV)
MMSE 15–30
OmegAD Study
1720 mg/die DHA+
600 mg/die EPA
Placebo: 4000 mg
corn oil
Both groups: + 16
mg/die vitamin E
12 months
There was no
significant statistical
difference after 6- or
12-month treatment
between groups in
MMSE, ADAS-cog,
CDR. A subgroup
with very mild
cognitive
dysfunction showed
a reduction in
decline rate.
[64]
204
AD (DSM-IV)
MMSE 15–30
OmegAD Study
1720 mg/die DHA+
600 mg/die EPA
Placebo: 4000 mg
corn oil
Both groups: + 16
mg vitamin E
12 months
Supplementation
with omega-3 did not
result in marked
effects on
neuropsychiatric
symptoms except for
possible positive
effects on depressive
symptoms (assessed
by MADRS) in
non-APOEε4 carriers
and agitation
symptoms (assessed
by NPI) in APOEε4
carriers.
[65]
46
AD
AD (DSM-IV)
MMSE 10–26
CDR-score 1–2
720 mg/die DHA+
1080 mg/die EPA
Placebo: Olive oil
Both groups: + 1.2
mg hydroquinone +
12 mg tocopherols
6 months
The treated group
did not show an
improvement in
cognitive symptoms
measured by MMSE,
ADAS-cog, HDR but
a relative
improvement in
CIBIC-plus score. In
a subgroup with
subjects with mild
cognitive
impairment (MMSE
>27 e CDR 0.5–1)
there was an
improvement in
ADAS-cog.
[66]
402
AD MMSE 14–26
Alzheimer’s
Disease
Cooperative Study
(ADCS) DHA
Supplementation
Trial USA
2000 mg/die DHA
from seaweed
Placebo: Corn or soy
oil
18 months
Supplementation
with DHA compared
with placebo did not
slow the rate of
cognitive and
functional decline in
patients with mild to
moderate
Alzheimer’s disease
assessed by MMSE,
ADAS-cog, CDR,
ADS-ADL, NPI.
[67]
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Table 7. Cont.
N◦ Patients PopulationCharacteristic
Type and Dose
Supplementation
Exposure
Period Results References
225 AD Souvenir IStudy
1700 mg/die DHA+
600 mg/die EPA
(Souvenaid)
Placebo: Control
drink
6 months
Supplementation
with omega -3
improved delayed
verbal recall.
However, ADAS-cog,
CIBIC-plus, NPI,
ADCS-ADL,
ADSC-ADL were
unchanged.
[68]
225 AD Souvenir IStudy
1700 mg/die DHA+
600 mg/die EPA
(Souvenaid)
Placebo: Control
drink
6 months
Souvenaid had a
positive result on
ADAS-cog outcome.
A higher intake of
Souvenaid was also
associated with
greater cognitive
benefit.
[69]
238 AD Souvenir IIStudy
1200 mg/die DHA+
300 mg/die EPA
(Souvenaid)
Placebo: Control
products
6 months
In the active group,
the NTB memory
domain increased.
[70]
527 AD MMSE 14 – 24Connect Study
1200 mg/die DHA+
300 mg/die EPA
(Souvenaid)
Placebo: Control
products
6 months
Cognitive
performance, as
assessed by
ADAS-cog, showed a
decline over time in
both control and
active study groups,
with no significant
difference between
study groups.
Add-on intake of
Souvenaid did not
slow cognitive
decline in persons
treated for
mild-to-moderate
AD.
[71]
174
AD mild to
moderate
OmegAD Study
1720 mg/die DHA+
600 mg /die EPA
Placebo: 4000 mg
corn oil
12 months
Plasma transthyretin
positively correlated
with MMSE and
inversely with
ADAS-Cog,
suggesting a
potential mechanism
for probable positive
effects of omega-3 on
cognition.
[72]
39
AD MMSE 15–26
CDR 0.5–1.0 Not
depressed (CESD
<4.0)
675 mg/die DHA+
975 mg /die EPA
Group omega-3 plus
alpha lipoic acid
(LA): 675 mg/die
DHA+ 975 mg/die
EPA+ 600 mg/die LA
Placebo: Soy oil
12 months
Active groups were
no different from the
placebo group in
ADAS-cog, ADL.
Omega-3 + LA group
showed less decline
assessed by MMSE.
IADL differences
between placebo e
omega-3 and
between placebo e
omega-3 + LA
groups were
observed.
[73]
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Table 7. Cont.
N◦ Patients PopulationCharacteristic
Type and Dose
Supplementation
Exposure
Period Results References
179 AD mild SouvenirII Study
1700 mg/die DHA+ 6
mg/die EPA
(Souvenaid)
Placebo: Control
drink
6 months
The administration
contributed to the
maintenance of the
organization of brain
networks in mild AD
patients.
[74]
19 AD MMSE 16–30
625 mg/die DHA+
600 mg/die EPA
Placebo: Olive oil
Both groups: + 20
mg mixed
tocopherols
4 months
The daily
supplementation
was associated with
none or only
negligible benefits on
mood and cognition,
assessed by MMSE,
HVLT-R, BASDEC,
BADLS.
[75]
204 AD OmegADStudy
1720 mg/die DHA+
600 mg/die EPA
Placebo: 4000 mg
corn oil Both groups:
+ 16 mg vitamin E
6 months
The daily
supplementation
stabilized the
cognitive
performance of AD
subjects, assessed by
ADAS-cog and
MMSE scores.
[76]
204 AD OmegADStudy
1720 mg/die DHA+
600 mg/die EPA
Placebo: 4000 mg
corn oil Both groups:
+ 16 mg vitamin E
6 months
A decrease was
observed in RvD1
and LXA4
production from
peripheral blood
mononuclear cells of
AD patients who did
not receive omega-3
but not in cells of AD
subjects under
omega-3 intake.
[77]
201
AD Open label
extension study
(OLE) Souvenir II
MMSE ≥ 20
1200 mg/die DHA+
300 mg/die EPA
(Souvenaid)
Placebo: Control
drink
6 months
The intake of
Souvenaid was well
tolerated with a
favorable safety
profile. The
adherence to
Souvenaid was very
high reflecting its
good tolerability and
ease of use.
[78]
171 AD OmegADStudy
1720 mg/die DHA+
600 mg/die EPA
Placebo: 1 g corn oil
Both groups: + 16
mg vitamin E
6 months
The effect of omega-3
supplementation on
MMSE and CDR
appeared to be
influenced by
homocysteine
plasma levels.
[79]
In a subgroup with very mild AD (MMSE > 27 and CDR 0.5–1), there was a significant reduction
in decline rate between the intervention and placebo groups in the first six months.
In a second paper published in 2008, Freund-Levi et al. [65], using the same sample from 2006,
showed that supplementation with omega-3 in patients with mild to moderate AD did not result in
marked effects on neuropsychiatric symptoms except from possible positive effects on depression
(assessed by MADRS) in non-APOEε4 carriers and agitation symptoms (assessed by Neuropsychiatric
Inventory, NPI) in APOEε4 carriers. The omega-3 mechanism of action in the brain in relation to
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behavior is not fully elucidated. It has been shown in in vitro studies that a combination of EPA and
DHA inhibits protein kinase C (PKC) activity [65]. Since mood stabilizers are known to inhibit PKC
activity as well, PKC inhibition may represent a common mode of action for omega-3 in bipolar
disorders. Other possible mechanisms could be that omega-3 fatty acids affect neurotransmitter levels
and membrane fluidity also by decreasing production of pro-inflammatory eicosanoids that might be
elevated in depression [65].
Chiu et al. [66] studied 46 subjects with mild to moderate AD or mild cognitive impairment
(DSM-IV: MMSE 10–26, CDR-score 1–2). During six months, the intervention group received 720 mg/die
DHA and 1080 mg/die EPA, while the placebo group received olive oil. Medication for AD treatment
was not allowed. There was no significant statistical difference in MMSE, ADAS-cog, and HDRS
between the two groups. The negative results of cognitive assessments support the previous studies
by Freund-Levi et al. [64,65], and all of the studies showed there might be a positive effect of omega-3
fatty acids only in subgroups with mild cognitive deficits. A significant improvement was observed in
clinician interview-based impression of change, plus carer interview (CIBIC-plus) in the intervention
group compared to the placebo group. This might be explained considering the cognitive and
behavioral aspects rather than the functional one. Omega-3 fatty acids may have been proposed to
have beneficial effects on mood, although this is an unlikely explanation for these results because of
the rigorous exclusion of people with significant depression and the absence of association with HDRS
score. The relative progress of general clinical conditions might have been caused by improvement in
cardiovascular or immunological systems induced by omega-3 [66].
In a subgroup, participants with mild cognitive impairment (MMSE >27 e CDR 0.5–1) but not
with AD, showed a significant additional delay in ADAS-cog, decline compared to the placebo group.
Quinn et al. [67] assessed 402 subjects with mild to moderate AD. The intervention group received
DHA 2000 mg/die from seaweed and the placebo group received corn or soy oil for 18 months.
Medication for AD treatment was allowed. Supplementation with DHA compared with placebo did
not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer’s
disease (no beneficial effect on the rate of change on MMSE, ADAS-cog, CDR, ADS-ADL, and NPI).
Sheltens et al. [68] assessed 225 subjects with mild AD. The intervention group received DHA
1700 mg/die and EPA 600 mg/die from a medical food named Souvenaid and the placebo group
received a control drink for six months. Significant improvement in the delayed verbal recall task
was noted in the supplemented group compared with control. ADAS-cog and other outcome scores
(CIBIC-plus, NPI, ADCS-ADL) remained unchanged.
The same authors published a study [69] where the same above-mentioned population was
divided into two subgroups: Patients with ‘low’ baseline ADAS-cog scores (<25.0) and patients with
‘high’ baseline ADAS-cog scores (≥25.0). Repeated measures models were used to determine the
relationship between ADAS-cog score and intervention. Baseline ADAS-cog significantly influenced
the effect of Souvenaid intervention on ADAS-cog outcome. A higher intake of medical food was also
associated with greater cognitive benefit.
Based on these results, two double-blind, randomized controlled clinical trials were designed.
The Souvenir II study examined the effect of longer treatment duration (six months) with
Souvenaid, as compared with control product on memory performance in drug-naïve mild AD [70].
Neuropsychological test battery (NTB) memory domain increased in the active group.
Considering that ADAS-cog could be considerably modified in moderate AD and that Souvenaid
had not been evaluated in patients with moderate AD already taking AD medications, a novel
S-Connect study was planned. This double-blind, parallel, randomized, controlled clinical study,
investigated the efficacy and tolerability of Souvenaid in 527 persons with mild to moderate AD,
consuming constant doses of Souvenaid [71]. Cognitive performance evaluated by ADAS-cog, showed
a decline over time in either placebo or active groups, indicating no significant difference between
active groups themselves. Souvenaid drinking did not decelerate cognitive decline in patients treated
for mild to moderate AD. Faxen-Irving et al., as a part of a previously published study on a DHA
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rich supplementation to subjects with AD [64], explored the effects of transthyretin on plasma and
CSF. Since plasma transthyretin correlated with MMSE and inversely with ADAS-Cog, these authors
suggest a potential mechanism for probable positive effects of omega-3 on cognition.
A study from Shinto et al. [73] investigated 39 subjects with probable AD in a randomized
placebo-controlled pilot with three arms, one group receiving only omega-3 fatty acids (DHA 675 mg/die
and EPA 975 mg/die), the second with the addition of alpha lipoic acid (600 mg/die), and the placebo
group receiving soy oil. The intervention lasted 12 months and medication for AD was allowed. No
differences were found in ADAS-cog and ADL between placebo and omega-3 fatty acids or between
placebo and omega-3 fatty acids + alpha lipoic acid. In MMSE, the mean variation between the placebo
group and the intervention group with only omega-3 fatty acids was not significant, whereas the
difference between placebo and omega-3 fatty acids + alpha lipoic acid was significant. The mean
IADL variation (Table 3) was significant between the placebo group and the omega-3 fatty acid group
and between the placebo and the omega-3 fatty acids + alpha lipoic acid group.
In a secondary analysis of the Souvenir II study [74], results suggest that Souvenaid maintains the
brain networks’ organization in patients with mild AD within six months, theoretically contrasting
with the progressive network disruption over time in AD. These results strongly support the hypothesis
that Souvenaid influences synaptic integrity and functioning.
Phillips et al. [75] assessed omega-3 fatty acids’ supplementation in 19 subjects with AD.
The intervention group received daily omega-3 fatty acids in the dosages of 625 mg DHA and
600 mg EPA and the placebo group received olive oil for four months. The daily supplementation was
associated with none or only negligible benefits on mood and cognition assessed by MMSE, the Hopkins
verbal learning test-revised (HVLT-R), brief assessment schedule depression cards (BASDEC) and
Bristol’s activities of daily living scale (BADLS).
Data obtained in the OmegAD study [65,80] were collected to examine the relationship of plasma
omega-3 levels with cognitive scores (using ADAS-cog and the MMSE) [76]. The daily supplementation
stabilizes the cognitive performance of AD subjects assessed by ADAS-cog and MMSE scores.
Also from the OmegAD study, a decrease was observed in resolvin D1 (RvD1) and lipoxin A4
(LXA4) production from peripheral blood mononuclear cells of AD patients who did not receive
omega-3 supplementation but not in the cells of AD subjects under omega-3 intake [77].
Recent systematic meta-analysis did not show any significant benefits of omega-3 fatty acids
supplementation in the treatment of mild to moderate AD, even if the treatment did not raise any
substantial safety issues [13]. In fact, studies concerning the tolerability, safety, and effect size
of Souvenaid demonstrated that the use of medical food for up to 12 months was well tolerated,
with a favorable safety profile and high adherence of intake [78,81]. Moreover, the efficacy of
omega-3 supplementation seems to be influenced by the baseline levels of plasma total homocysteine,
suggesting that adequate B vitamin status is required to obtain beneficial effects of omega-3 on cognitive
performance in moderate AD [79].
4. Materials and Methods
The authors searched PubMed, Web of Science, and Scopus articles using a combination of
“omega-3 fatty acids,”, “Parkinson’s Disease, “Alzheimer’s Disease”, “clinical trials” as keywords.
Inclusion criteria consisted of original intervention studies, controlled by placebo, that assessed omega-3
polyunsaturated fatty acids impact on cognitive function in humans with PD or AD, until May 2019,
without restriction for the initial date of publication. We searched for interventions using omega-3
polyunsaturated fatty acids as dietary supplements or as increased dietary intake (such as fish or fish
oils). First, we evaluated the titles and abstracts, then, we completed the reading of the full texts.
Two reviewers independently performed the paper search, selection, and result extraction.
In order to favor reliability, data were collected independently in a table including the number of
patients, population characteristics, type and dose of supplementation, exposure period, results and
references. The authors prepared references using Zotero as bibliography software.
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5. Conclusions
Neurodegenerative conditions, such as Parkinson’s disease and Alzheimer’s disease, represent
a challenging issue in clinical medicine, and their burden is expected to increase dramatically
in the forthcoming decades. At the present time, no etiological treatment is routinely available,
and medical therapy is mainly symptomatic. The adoption of a nutritional approach would be
highly recommendable.
Omega-3 fatty acids represent an interesting biological potential, in view of their anti-inflammatory
and metabolic properties, in the management of these diseases.
Indeed, the evidence deriving from prospective observational studies is encouraging, both for
Parkinson’s and Alzheimer’s disease. The adoption of a dietary regimen enriched with omega-3
fatty acids rather consistently associates with a reduced risk of either condition. On the other hand,
randomized trials have provided conflicting results, and many of them have failed to document a
definite protective effect. This was confirmed by most reviews and meta-analyses performed so far.
The inconsistency between observational and randomized studies is not unusual in clinical
research, particularly when considering treatment with dietary supplements or integrators. A number
of reasons may account for this finding. Firstly, in controlled trials, dietary supplementation is usually
carried out over a relatively limited time span, compared with the life-long exposure of real-life
observational studies. The different time course of the two approaches could play a relevant role.
Observational studies may disclose the preventive effects of disease initiation, whereas in randomized
trials involving patients already carrying a disease, the outcome more likely consists of a slowing of
disease progression, or a reduction in disease-related complications. Distinct protective mechanisms
are likely to take place. Furthermore, the variations in dietary patterns might reflect the adoption of
a healthier lifestyle, in adjunct to the contribution provided by the single-nutrient supplementation.
This was postulated, for instance, when investigating the protective effects of the Mediterranean diet
on cognitive performances. In the present context, the intake of higher amounts of foods containing
omega-3 fatty acids might be associated with a reduced intake of other nutrients, such as meat.
Finally, the possibility of different individual responses to dietary intervention must be considered.
As mentioned in this review, the protective effects exerted by omega-3 fatty acids are likely to be
modulated by patient-related factors, some of which may have a significant genetic component and
may, therefore, be unmodifiable, and unpredictable with routine clinical and biochemical evaluation.
At any rate, treatment with omega-3 fatty acids was generally reported to be safe and well-tolerated.
In our opinion, they may indeed represent a valuable and biologically plausible tool in the management
of neurodegenerative diseases. Of course, supplementation needs to be a part of a global lifestyle
intervention and has to take place in the early stages of the disease, when a benefit may be detected.
Hopefully, in the near future the adoption of personalized treatment strategies, aimed to predict
individual responses, will help to optimize the effectiveness of such intervention, in order to face the
progressive rise of these devastating conditions.
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5-LOX 5-lipoxygenase
AD Alzheimer’s disease
ADAS-Cog Alzheimer’s disease assessment scale–cognitive subscale
ADCS Activities of daily living scales
ALA α linolenic acid
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ApoE apolipoprotein E
APP amyloid precursor protein
ARA arachidonic acid
Aβ amyloid beta peptide
BADLS Bristol’s activities of daily living scale
BASDEC brief assessment schedule depression cards
BBB blood–brain barrier
BDI Beck depression inventory scale
CDR clinical dementia rating scale
CGI clinical global impression scale
CIBIC-Plus clinician interview-based impression of change, plus carer interview
COX cyclooxygenase
cPLA2 cytosolic calcium-dependent phospholipase A2
CSF cerebrospinal fluid
DHA docosahexaenoic acid
DHA-FFA free nonesterified form docosahexaenoic acid
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, fourth edition
EPA eicosapentaenoic acid
FABPs fatty acid binding proteins
HDRS Hamilton depression rating scale
hs-CRP C-reactive protein
HVLT-R Hopkins verbal learning test–revised
iPLA2 cytosolic calcium-independent phospholipase A2
LA linoleic acid
LXA4 lipoxin A4
MADRS Montgomery–Åsberg depression rating scale
MMSE mini-mental state examination
MUFAs monounsaturated fatty acids
NPI Neuropsychiatric Inventory
NTB neuropsychological test battery
PD Parkinson’s disease
PKC protein kinase C
PLA2 phospholipase A2
PUFAs omega-3 polyunsaturated fatty acids
sPLA2 secretory phospholipase A2
RvD1 resolvin D1
TAC total antioxidant capacity
UPDRS unified Parkinson’s disease rating scale
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